Treatment with a peptide that mimics the naturally occurring protein GIV prevents immune overreaction and supports a mechanism critical for survival in mouse models of sepsis and colitis, according to a UC San Diego study.
J. Silvio Gutkind, PhD, has been named chair of the Department of Pharmacology at UC San Diego School of Medicine.
Analyzing anonymized patient medical records, UC San Diego researchers discovered that cholesterol-lowering statins reduced risk of severe COVID-19 infection, while lab experiments uncovered a cellular mechanism that helps explain why.
A consortium of 12 health systems, led by UC San Diego Health, introduces COVID19questions.org, a site where clinicians, researchers, patients and the general public are invited to submit questions that could be answered by COVID-19 patient medical record data from 200+ hospitals.
UC San Diego researchers discovered that the SARS-CoV-2 virus can’t grab hold of cell receptor ACE2 without a carbohydrate called heparan sulfate, which is also found on lung cell surfaces — disrupting that interaction with a repurposed drug may help treat COVID-19.
UC San Diego researchers demonstrate that one dose of their version of CRISR gene editing can chew up toxic RNA and almost completely reverse symptoms in a mouse model of myotonic dystrophy, a type of adult-onset muscular dystrophy.
An elusive protein that many consider the key of fully understanding the causes of genetic Parkinson’s disease has come much more clearly into focus. Impacting millions around the world, Parkinson’s is a neurological disorder that progressively attacks motor functions.
UC San Diego researchers discovered that people with an inactive RNA-editing enzyme respond better to cancer immunotherapy, and inhibitors of the enzyme help mice with difficult-to-treat cancers live longer.
By analyzing the FDA database of adverse drug effects, UC San Diego researchers discovered that people who received Botox injections — not just in the forehead — reported depression significantly less often than patients undergoing different treatments for the same conditions.
By inhibiting the molecule AKT, UC San Diego researchers favor the culture of human spermatogonial stem cells in the lab, a first step toward lab-produced sperm as a treatment for male infertility.